AR084222A1 - Derivados de amido-piridina como antagonistas del receptor ep4 - Google Patents

Derivados de amido-piridina como antagonistas del receptor ep4

Info

Publication number
AR084222A1
AR084222A1 ARP110104603A ARP110104603A AR084222A1 AR 084222 A1 AR084222 A1 AR 084222A1 AR P110104603 A ARP110104603 A AR P110104603A AR P110104603 A ARP110104603 A AR P110104603A AR 084222 A1 AR084222 A1 AR 084222A1
Authority
AR
Argentina
Prior art keywords
alkane
group
amido
alkanes
halogens
Prior art date
Application number
ARP110104603A
Other languages
English (en)
Inventor
Fabrizio Colace
Manuela Borriello
Lucio Rovati
Luigi Piero Stasi
Benedetta Buzzi
Original Assignee
Rottapharm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rottapharm Spa filed Critical Rottapharm Spa
Publication of AR084222A1 publication Critical patent/AR084222A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente relata un derivado de amido-piridina de fórmula (1) o una sal farmacéuticamente aceptada del mismo, donde R1 y R2 son independientemente hidrógenos, alcanos lineales o ramificados C1-3 o conectados formando un anillo de ciclopropano; R es independientemente seleccionado del grupo consistente en halógenos y trifluorometilo y p es 1, 2 ó 3; A es C o N; E es un grupo de fórmula (B) ó (C), donde B es C(O)OH, C(O)O-alcano C1-3, y C es seleccionado del grupo de fórmulas (2); m es 1, 2 ó 3, n es 0 ó 1; W es -O-, -O(alcano C1-3)-; -(alcano C1-3)O-; -C(O)-; -C(=N-O(alcano C1-3))-; -NH- o -NH(alcano C1-3)-; Ar es fenil, opcionalmente sustituido por uno o más sustitutos seleccionados del grupo consistente en halógenos, trifluorometilo, trifluorometoxilo, metilo, -NH(alcano C1-3)-; -N(alcano C1-3)(alcano C1-3)-, un anillo heterocíclico de 5 a 7 miembros que contiene un átomo de nitrógeno el cual está enlazado covalentemente a Ar y opcionalmente conteniendo uno o dos heteroátomos seleccionados de N, O y S; y un anillo heteroaromático de 5- ó 6- miembros que contiene 1 a 3 heteroátomos seleccionados de S, O y N, dicho anillo heteroaromático siendo sustituido por uno o más substitutos seleccionados del grupo consistente de alcanos C1-3, cicloalcoxi C3-5, alcano C1-3carbonilo. Los compuestos de la presente pueden ser usados para la producción de un medicamento para el tratamiento de patologías que requieren el uso de un antagonista de receptor EP4, tales como el tratamiento de dolor agudo y crónico, dolor inflamatorio, osteoartritis, desórdenes asociados a inflamaciones como artritis, artritis reumatoidea, cáncer, endometriosis y migraña.
ARP110104603A 2010-12-10 2011-12-12 Derivados de amido-piridina como antagonistas del receptor ep4 AR084222A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2010/069355 WO2012076063A1 (en) 2010-12-10 2010-12-10 Pyridine amide derivatives as ep4 receptor antagonists

Publications (1)

Publication Number Publication Date
AR084222A1 true AR084222A1 (es) 2013-05-02

Family

ID=43585625

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110104603A AR084222A1 (es) 2010-12-10 2011-12-12 Derivados de amido-piridina como antagonistas del receptor ep4

Country Status (7)

Country Link
US (1) US8828987B2 (es)
EP (1) EP2649061B1 (es)
AR (1) AR084222A1 (es)
CA (1) CA2820109C (es)
ES (1) ES2545110T3 (es)
TW (1) TW201307314A (es)
WO (1) WO2012076063A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112015028501B8 (pt) * 2013-05-17 2023-01-24 Incyte Corp Compostos derivados de bipirazol, seus sais, composição compreendendo o composto ou o sal, método de inibição in vitro de uma atividade de jak1, e processo de preparação de sal de ácido fosfórico
TR201807659T4 (tr) 2013-06-12 2018-06-21 Kaken Pharma Co Ltd 4-alkinil imidazol türevi ve etken madde olarak bunu içeren ilaç.
FI3364958T3 (fi) * 2015-10-23 2023-04-06 Navitor Pharm Inc Sestriinin ja gator2:n vuorovaikutuksen modulaattoreita ja niiden käyttötapoja
CR20180323A (es) 2015-11-20 2018-08-06 Idorsia Pharmaceuticals Ltd Derivados de indol n-sustituídos como moduladores de los receptores de pge2
CA2968836A1 (en) 2016-06-13 2017-12-13 Gilead Sciences, Inc. Fxr (nr1h4) modulating compounds
CN110461328A (zh) 2017-03-28 2019-11-15 吉利德科学公司 治疗肝疾病的治疗组合
WO2018210988A1 (en) 2017-05-18 2018-11-22 Idorsia Pharmaceuticals Ltd Pyrimidine derivatives as pge2 receptor modulators
KR102612649B1 (ko) 2017-05-18 2023-12-11 이도르시아 파마슈티컬스 리미티드 Pge2 수용체 조절제로서의 벤조푸란 및 벤조티오페논 유도체
US11446298B2 (en) 2017-05-18 2022-09-20 Idorsia Pharmaceuticals Ltd Pyrimidine derivatives
DK3625224T3 (da) 2017-05-18 2021-11-08 Idorsia Pharmaceuticals Ltd N-substituerede indolderivater
UA125123C2 (uk) 2017-05-18 2022-01-12 Ідорсія Фармасьютікалз Лтд Фенільні похідні як модулятори pge2 рецепторів
MA51829A (fr) 2018-02-16 2020-12-23 Incyte Corp Inhibiteurs de la voie jak1 pour le traitement de troubles liés aux cytokines
MA52219A (fr) 2018-03-30 2021-02-17 Incyte Corp Traitement de l'hidradénite suppurée à l'aide d'inhibiteurs de jak
KR20210040064A (ko) * 2018-07-12 2021-04-12 로타팜 바이오테크 에스.알.엘 Ep4 수용체 길항제로서의 (r)-4-(1-(1-(4-(트리플루오로메틸)벤질)피롤리딘-2-카복스아미드)사이클로프로필 벤조산
CN118388474A (zh) 2019-02-19 2024-07-26 吉利德科学公司 Fxr激动剂的固体形式
IL298118A (en) 2020-06-02 2023-01-01 Incyte Corp Processes for making jak1 inhibitor
TW202227447A (zh) * 2020-08-18 2022-07-16 大陸商和記黃埔醫藥（上海）有限公司 嘧啶酮類化合物及其用途
US20230390303A1 (en) 2020-11-13 2023-12-07 Ono Pharmaceutical Co., Ltd. Cancer treatment by combination of ep4 antagonist and immune checkpoint inhibitor
MX2023006542A (es) 2020-12-08 2023-08-25 Incyte Corp Inhibidores de la vía cinasa jano 1 (jak1) para el tratamiento del vitiligo.
JP2024533565A (ja) * 2021-09-14 2024-09-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ３－フェノキシアゼチジン－１－イル－ヘテロアリールピロリジン誘導体及び医薬としてのその使用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020111495A1 (en) 1997-04-04 2002-08-15 Pfizer Inc. Nicotinamide acids, amides, and their mimetics active as inhibitors of PDE4 isozymes
US6211197B1 (en) 1998-10-07 2001-04-03 Merck Frosst Canada & Co. Prostaglandin receptor ligands
AP2006003534A0 (en) 2003-09-03 2006-04-30 Pfizer Phenyl or pyridyl amide compounds as prostaglandin E2 antagonists.
JP4054369B2 (ja) 2004-05-04 2008-02-27 ファイザー株式会社 オルト置換アリールまたはヘテロアリールアミド化合物
EA200601847A1 (ru) 2004-05-04 2007-04-27 Пфайзер Инк. Замещённые метиларил- или гетероариламидные соединения
JP5244091B2 (ja) 2006-04-24 2013-07-24 メルク カナダ インコーポレイテッド Ｅｐ４受容体アンタゴニストとしてのインドールアミド誘導体
EP2054401B1 (en) 2006-08-11 2013-05-01 Merck Canada Inc. Thiophenecarboxamide derivatives as ep4 receptor ligands
AU2008221194B2 (en) 2007-02-26 2013-06-27 Merck Canada Inc. Indole and indoline cyclopropyl amide derivatives as EP4 receptor antagonists
CA2724077C (en) 2008-05-14 2016-04-26 Astellas Pharma Inc. Amide compound

Also Published As

Publication number Publication date
TW201307314A (zh) 2013-02-16
US20130261100A1 (en) 2013-10-03
CA2820109C (en) 2018-01-09
ES2545110T3 (es) 2015-09-08
EP2649061A1 (en) 2013-10-16
EP2649061B1 (en) 2015-05-13
WO2012076063A1 (en) 2012-06-14
US8828987B2 (en) 2014-09-09
CA2820109A1 (en) 2012-06-14

Similar Documents

Publication Publication Date Title
AR084222A1 (es) Derivados de amido-piridina como antagonistas del receptor ep4
GEP20166472B (en) Androgen receptor modulating compounds
EA201591204A3 (ru) Новые хиральные n-ацил-5,6,7,(8-замещенные)-тетрагидро-[1,2,4]триазоло[4,3-а]пиразины как селективные антагонисты рецептора nk-3, фармацевтическая композиция, способы применения при нарушениях, опосредованных nk-3 рецепторами, и их хиральный синтез
PE20110854A1 (es) DERIVADOS DE 1-FENIL-1H-PIRAZOLO[3,4-c]PIRIDINA-4-CARBONILAMINA COMO ANTAGONISTAS DE LOS RECEPTORES CCR1
EA201001724A1 (ru) Производные изоксазола и их применение в качестве потенциирующих средств для метаботропных глутаматных рецепторов
PE20141050A1 (es) Inhibidores de quinasa relacionados con pirrolo (2,3-d) pirimidina tropomiosina
AR095885A1 (es) Compuestos derivados de arilpirrolopiridina como inhibidores de lrrk2
PE20160589A1 (es) Heteroaril-ciclohexil-tetraazabenzo[e]azulenos como antagonistas de los receptores de vasopresina v1a
EA201290940A1 (ru) Новые соединения как селективные антагонисты рецептора nk3, фармацевтическая композиция и методы их использования при нарушениях, опосредованных nk3 рецепторами
PE20160523A1 (es) Derivados de arilo o heteroarilo como inhibidores de moleculas pequenas de fibrosis
AR083831A1 (es) Antagonistas del receptor del cgrp de piperidinona carboxamida azaindano
IN2014MN02106A (es)
BR112015032637A2 (pt) derivados de pirrolopiridina ou pirazolopiridina
PE20121639A1 (es) Derivados de 3-hidroxi-5-arilizotiazol como moduladores de gpr40
AR077227A1 (es) Compuesto de acido aril/ heteroaril- sustituido carboxilico, su uso para fabricar un medicamento util el tratamiento de afecciones o trastornos mediados por receptores s1p1, tales como esclerosis multiple y composicion farmaceutica que lo comprende
AR066421A1 (es) Compuestos derivados de piridona
MX353209B (es) Antagonistas d2, metodos de sintesis y metodos de uso.
EA201300122A1 (ru) Циклические n,n'-диарилтиомочевины и n,n'-диарилмочевины - антагонисты андрогеновых рецепторов, противораковое средство, способ получения и применения
AR110241A1 (es) Ácidos indanilaminopiridil-ciclopropano-carboxílicos, composiciones farmacéuticas y usos de los mismos
ATE530182T1 (de) Pharmazeutische zubereitungen enthaltend nk1- rezeptoren antagonisten und natriumkanal blockierende verbindungen
CL2012000967A1 (es) Compuestos derivados de amida de los acidos indazol-4-carboxilico y 1-h-pirazolo[3,4-c]piridina-4-carboxilico, agonistas del receptor ccr1; composicion farmaceutica; utiles en el tratamiento de inflamaciones cronicas, alergias, soriasis, artritis reumatoidea, esclerosis multiple, diabetes tipo 1, entre otras.
ATE530187T1 (de) Pharmazeutische zubereitungen mit nk1-rezeptor- antagonisten und natriumkanalblockern
AR092288A1 (es) Ligandos del receptor ep1
RU2017120030A (ru) Новый тип производного цитидина и его применение
TR201910220T4 (tr) Prostat kanserinin tedavisine yönelik ikame edilmiş 2-tiokso-imidazolidin-4-onlar ve bunların spiro analogları, aktif anti-kanser içerik maddesi, farmasötik bileşim, tıbbi preparasyon, yöntem.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal